/photos/antibody-production.jpg

Recombinant antibody production service

Icosagen Cell Factory provides recombinant antibody production services using proprietary QMCF Technology.

Production of recombinant antibodies offers several opportunities for molecule modifications such as antibody subtype exchange, partial humanization or generation of Fab and F(AB)2 fragments. Service may also include antibody variable region-encoding cDNA isolation from hybridoma or from the B-cells of immunized animals and cDNA synthesis. 

Two options for recombinant antibody production using QMCF Technology are available:

  1. Small scale pilot studies could be performed within 3-4 weeks, if high copy number pQMCF-T expression vectors are used for transient production
  2. For large scale production, pQMCF expression vectors are used that allow generation of stable episomal production pools and cell banks. Production volume scale-up to 1-20 litres allows for cost effective production ranging from hundreds of milligrams up to grams of antibodies within 6 weeks, starting with cloning, until delivery of the requested amount of purified antibodies.


Transient production includes:

  • cDNA optimization and cloning into transient pQMCF-T expression vector
  • Chemical transfection of the QMCF/CHOEBNALT85 cell line and expression control 48 hours after transfection
  • Culture expansion (up to 2.5 fold) and antibody production
  • Harvesting and purification
  • Product analysis and characterization

Stable production, including selection and cell bank generation:

  • cDNA optimization and cloning into pQMCF expression vector
  • Electroporation of the QMCF/CHOEBNALT85 cell line and expression control 48 hours after transfection
  • G418 selection and generation of production cell bank (stable episomal pool)
  • Culture expansion to the final production volume and antibody production 
  • Harvesting and purification
  • Product analysis and characterization 

Each project will be tailored according to the customer's needs; however, the work-flow below describes all options available under this recombinant antibody production service.